Fig. 6From: Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival modelMont-Carlo Simulation and Strategy selection diagram of CUA of compared strategies in the first-line treatment of HR + / HER2- MBCBack to article page